# A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07026279/  
OnCo record `nct07026279` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of narmafotinib ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.

## Summary

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07026279 by Amplia Therapeutics Limited, with 67 participants enrolled, started 2025-08-18 and due to reach its primary completion in 2029-07. Interventions recorded: narmafotinib ascending doses and narmafotinib dose comparison.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07026279
- Phase: 1/2
- Setting: A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients
- Sponsor: Amplia Therapeutics Limited
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT07026279: https://clinicaltrials.gov/study/NCT07026279

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07026279.json